"studyid","tsseq","tsvcdref","actsub","adapt","addon","agemax","agemin","agespan","dcutdesc","dcutdtc","dose","dosfrq","dosu","fcntry","hltsubji","indic","intmodel","inttype","length","narms","objprim","objsec","outmspri","pclas","plansub","random","regid","route","sendtc","sexpop","sponsor","sstdtc","stoprule","stype","tblind","tcntrl","tdigrp","tindtp","title","tphase","trt","ttype","adminact_im","siteid_im","tblind_im","agespan_iri_im","tsvcdref_iri_im","objprim_seq_im","objsec_seq_im"
"CDISCPILOT01","1","","254",,"N","NULL","P50Y","ADULT (18-65)","Interim Analysis Data Cutoff Date",,"54","QD","mg",,,,,,"P26W","3","To determine if there is a statistically significant relationship between the change in both ADAS-Cog and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg])","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas.",,,"300","Y","NCT00987090","TRANSDERMAL",,"BOTH","CDISCPILOT01",,"Last patient completed last visit or sponsor decided to discontinue study",,"DOUBLE BLIND",,"Patients with Probable Mild to Moderate Alzheimer’s Disease","TREATMENT","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease.","PHASE II TRIAL",,"SAFETY",,,"DOUBLE_BLIND","ADULT","","1","1"
"CDISCPILOT01","1","CDISC",,"N",,,,,,,,,,,"N",,"PARALLEL","DRUG",,,,,,,,,,,,,,,,"INTERVENTIONAL",,"PLACEBO",,,,,,,,,,,"CDISC",,
"CDISCPILOT01","1","ISO 3166",,,,,,,,,,,,"USA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"ISO3166",,
"CDISCPILOT01","1","ISO 8601",,,,,,,,"2015-03-31",,,,,,,,,,,,,,,,,,,"2015-03-05",,,"2012-07-06",,,,,,,,,,,,,,,"ISO8601",,
"CDISCPILOT01","1","NDF-RT",,,,,,,,,,,,,,,,,,,,,,"Acetylcholine Release Inhibitor",,,,,,,,,,,,,,,,,,,,,,,"NDF-RT",,
"CDISCPILOT01","1","SNOMED",,,,,,,,,,,,,,"Alzheimer's Disease (Disorder)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"SNOMED",,
